Panavance Clinical Trials

Home
United States
Berwyn, PA
Panavance Clinical Trials

Panavance Therapeutics Inc. is developing GP-2250 for patients with pancreatic and ovarian cancer.

09/03/2024

September is Ovarian Cancer Awareness Month, a time to educate and heighten awareness about .

Ovarian cancer is the 8th most common cancer and the 5th leading cause of cancer death in women.

Panavance is developing misetionamide (GP-2250) for ovarian cancer.

We recently announced foundational preclinical results of misetionamide in ovarian cancer which demonstrated profound effects on tumor metabolism, anti-angiogenic activity, protein synthesis, and DNA transcription.

Learn more about our work here:
https://panavance.com/press/panavance-therapeutics-announces-foundational-publication-of-misetionamide-gp-2250-in-ovarian-cancer-in-the-journal-cancer-medicine/

08/27/2024

Panavance’s unique and novel mechanism of action selectively disrupts the energy metabolism of cancer cells leading to cancer cell death and restricting cancer cell growth.

Discover our science here: https://panavance.com/our-science/

08/21/2024

Panavance is bringing new hope to the fight against . We are currently conducting a Phase 1 clinical trial at major medical centers in to assess the safety, tolerability, and antitumor activity of misetionamide (GP-2250). Locations include:

- Philadelphia, PA
- Kansas City, KS
- Boston, MA
- Winston-Salem, NC

Learn more here: https://panavance.com/become-a-patient-or-clinician-participant/

08/13/2024

Panavance is deeply rooted in science which has led the development of our clinical program for .

With over 15 publications in the world’s peer-reviewed cancer journals, Panavance continues to pioneer groundbreaking research in including and .

Check out the publications here: https://panavance.com/resource-center/

08/06/2024

Clinical trials are crucial as they help advance medicines and improve health outcomes.

They also aim to improve patients’ quality of life by finding better ways to manage diseases.

We are currently recruiting for a Phase 1 trial for in several locations. This trial offers patients access to an innovative anticancer agent in addition to standard of care treatment.

Learn more here: https://panavance.com/become-a-patient-or-clinician-participant/

07/25/2024

Interested in learning the science behind misetionamide (GP-2250)?

Misetionamide is a broadly active, tumor cell selective cancer therapeutic that suppresses cancer cells by disrupting their energy metabolism and DNA transcription through NFkB inhibition.

Learn more about our unique science here: https://panavance.com/our-science/

07/19/2024

Our lead therapeutic candidate, misetionamide (GP-2250) has shown broad utility across several indications in studies.

Through our continued research and clinical trials, we aim to reach patients around the world who have been diagnosed with or cancer.

For more information about misetionamide, visit https://panavance.com/our-science/

07/11/2024

Misetionamide (GP-2250) is currently being tested in a Phase 1 to assess its safety, tolerability, and preliminary antitumor activity alongside standard care for cancer patients.

Our trial locations include:
• Philadelphia, PA
• Kansas City, KS
• Boston, MA
• Winston-Salem, NC

Learn more here: https://panavance.com/become-a-patient-or-clinician-participant/?fbclid=IwZXh0bgNhZW0CMTAAAR2ZePRWk8CJjmDMbOYUFkO2nTa6nUu7dV-3s5FsqheDt378lrNldcQ85Fw_aem_otpe96KfwrlblAWBPgCcSQ

07/02/2024

Interested in learning more about and why they are conducted?

A clinical trial is a carefully regulated research study that tests new treatments.

It is set by strict guidelines from the U.S. Food and Drug Administration and sets the standard for how researchers, doctors, and health professionals are treating patients in the safest manner possible.

Panavance is currently conducting their Phase 1 clinical trial for the treatment of .

Learn more here: https://panavance.com/become-a-patient-or-clinician-participant/

06/28/2024

Panavance’s lead therapeutic, misetionamide (GP-2250), is currently undergoing evaluation in a Phase 1 study to assess safety, tolerability, and initial antitumor activity when combined with standard cancer treatments.

Our clinical trial sites are located in:

Philadelphia, PA
Kansas City, KS
Boston, MA
Winston-Salem, NC

For further details about our , visit: https://panavance.com/become-a-patient-or-clinician-participant/

06/25/2024

At Panavance, our mission is to bring new hope to cancer patients. Our clinical-stage drug, misetionamide (GP-2250), shows promise in addressing pancreatic and ovarian cancers. With its unique mechanism of action, it aims to improve patient outcomes and quality of life.

Stay connected with us to learn more about our Phase 1 clinical study in pancreatic cancer: https://panavance.com/become-a-patient-or-clinician-participant/

06/13/2024

Curious about clinical trials? Let’s talk about informed consent.

Informed consent is the process of understanding a clinical trial before deciding to participate. The research team explains the trial's purpose, duration, procedures, potential risks, and benefits.

Once you've made your decision, you'll sign a consent form. Even after signing, you have the right to withdraw from the study at any time, for any reason.

Learn more about Panavance’s Phase 1 clinical study for the treatment of here: https://panavance.com/become-a-patient-or-clinician-participant/

Address

1055 Westlakes Drive, Suite 300, Berwyn, Pennsylvania, US
Berwyn, PA
19312

Telephone

+16109221910

Website

https://panavance.com/become-a-patient-or-clinician-participant/

Alerts

Be the first to know and let us send you an email when Panavance Clinical Trials posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Panavance Clinical Trials:

Shortcuts

Want your practice to be the top-listed Clinic in Berwyn?